entertainment -WSS

entertainment

author：explore 2025-08-23 08:57:48 - browse：5828

A sign of pharmaceutical company Bayer in front of a blossomed tree — coverage from STAT — INA FASSBENDER/AFP via Getty Images

More hopeful news on the menopause front: Bayer announced on Monday encouraging results in two Phase 3 trials for its non-hormonal drug candidate, elinzanetant, meant to treat hot flashes. The results follow the recent market launch of Veozah, Astellas Pharma’s groundbreaking non-hormonal treatment for hot flashes, which was approved by the U.S. Food and Drug Administration last spring and received approval in the U.K., under the name Veozah, in December.

Elinzanetant is a neurokinin-1 and 3 receptor antagonist, and works by calming down the estrogen receptors in the brain that become hyperactive around menopause, causing hot flashes. The drug, a pill administered once a day, was shown to reduce both the frequency and intensity of hot flashes, and also met the secondary endpoints for improving sleep and quality of life, according to JoAnn Pinkerton, professor of obstetrics and gynecology and director of the Midlife Health at UVA Health, who is a clinical investigator for Bayer’s drug candidate.

Pinkerton said she was excited to see the broader quality of life improvements through elinzanetant: “Women have more than just hot flashes — it’s actually more about hot flushes, sweats, fatigue, lack of sleep and some of the mood changes that go on during [menopause].”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： AltruBio raises $225 million to develop ulcerative colitis drug

explore

WSS

As health system earnings go up, health insurance stocks go down

For longer

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Questions and answers about ramping up H5N1 bird flu vaccine

Crowdfunding for medical bills sidesteps core problem, author says

As health system earnings go up, health insurance stocks go down

hotspot

entertainment

focus

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

The creative science of coining drug names

Medical records are filled with copy

Investigation reveals sickle cell patients pressured into sterilizations

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Questions and answers about ramping up H5N1 bird flu vaccine

United colonoscopy coverage change 'may cost lives,' doctors say

HHS's proposed rule does nothing to address the climate crisis

How to save PrEP access — and even expand it

Empower primary care with adequate payments and technology

hotspot

The effects of a landmark ruling on DNA ownership are becoming clearer

Investigation reveals sickle cell patients pressured into sterilizations

Can gargling with Listerine treat gonorrhea of the mouth?

Lawmakers grill UnitedHealth CEO on Change cyberattack

As a primary care physician, here's how I hope to partner with AI

At flashy new research hub, AstraZeneca lays out ambitious growth goals

focus

explore

entertainment

hotspot